Nuvation Bio Inc. (NUVB) - Quarterly EPS earnings growth

Official company branding of Nuvation Bio (NUVB)

Nuvation Bio Inc. bases its development on creating solid tumor therapies for patients and pharma partners. The business is completely independent of economic cycles, as success depends solely on the efficacy of the molecules. High costs for late-stage research create pressure, yet liquidity remains stable. This chart illustrates the quarterly EPS dynamics using GURU.Markets data, where 27.10 determines this parameter level.

Nuvation Bio (NUVB) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Nuvation Bio Inc.

- market value and analyst target forecast:
Fundamental company analysis:nuvationbio.com, NUVB
Manufactured product of Nuvation Corp

Nuvation Bio Inc. develops innovative cancer therapies amidst stringent geopolitical restrictions. Quarterly EPS growth measures the percentage change in net income per share, reflecting the business's financial resilience. The investor utilizes this trend to distinguish real growth from market volatility. However, sanctions blocking the logistics of bio-components create downside risks. By analyzing the volatility of the quarterly EPS figure, one can assess the company's adaptability to external shocks.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|DAWN (dayonebio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months monopartx.com (MNPR)|Year-over-year earnings per share growth for the last twelve months Inhibrx Corp (INBX)|IMAB - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc